CytoSorbents Reveals Financial Progress and Updates for DrugSorb-ATR in Q1 2026

CytoSorbents Financial Results and Regulatory Updates for Q1 2026

CytoSorbents Corporation, listed on NASDAQ as CTSO, recently disclosed its financial performance for the first quarter ending on March 31, 2026. Specializing in the treatment of severe medical conditions via blood purification technology, the company reported a modest revenue increase but faced challenges that impacted its overall financial results.

Financial Performance

In Q1 2026, CytoSorbents recorded revenues of $8.9 million, reflecting a 2% growth from $8.7 million in the same quarter the previous year. Despite this increase, the company's gross margin slightly decreased to 69% from 71% compared to Q1 2025. Significant efforts to address operational efficiency and strategic focus translated into reduced operating losses, which amounted to $3.0 million in Q1 2026, down from $3.9 million in the previous year.

However, the net loss widened to $5.1 million or $0.08 per share, compared to a loss of $1.5 million or $0.02 per share in Q1 2025. This shift was largely attributed to the non-cash impacts linked to changes in foreign currency transactions year-over-year. An adjusted net loss, excluding these fluctuations and stock compensation effects, shrank to $3.4 million or $0.05 per share.

Dr. Phillip Chan, the company’s CEO, commented on the performance, noting that the 13% growth in direct sales territories outside of Germany drove the revenue increase. Although the German sales team achieved marginally lower sales with fewer personnel, the focus on leadership and customer engagement was highlighted as a significant improvement area. The team aims for deliberate expansion to better penetrate the crucial German market.

Operational Adjustments

The CytoSorbents team implemented a strategic workforce reduction of roughly 10%, aimed at optimizing operational expenses. This contributed to reduced costs and improved operating margins in the first quarter. They continue to work on various operational enhancements that they believe will yield positive results moving forward.

Despite achieving some growth, distributor sales stagnated due to geopolitical tensions in areas like the Middle East, which resulted in approximately $500,000 in delayed orders. CytoSorbents remains optimistic about stabilizing market conditions and increasing growth through its Dubai subsidiary.

Regulatory Updates for DrugSorb-ATR

On the regulatory front, CytoSorbents had sought approval for its DrugSorb-ATR system designed to reduce perioperative bleeding during cardiac surgeries. In 2025, the FDA denied the initial application but provided no safety concerns, prompting CytoSorbents to prepare a new De Novo application incorporating additional necessary data. The pathway to compliance seems clearer now, as ongoing discussions with the FDA are expected to result in a novel submission by late 2026 or early 2027.

Clinical trials affirming the safety and efficacy of DrugSorb-ATR in patients who had recently stopped taking ticagrelor emerged in prominent peer-reviewed journals, reinforcing its clinical value and potential. Following the anticipated FDA approval for Brilinta, the company plans to explore expanding the indication to remove other direct oral anticoagulants (DOACs), targeting a $500 million to $1 billion annual market in cardiac surgeries.

Economic Efficiency in Critical Care

In connection with CytoSorb technology, a recent study published in a peer-reviewed journal underscored the cost-effectiveness of CytoSorb therapy in critically ill patients, particularly those with septic shock. This research emphasized significant benefits such as reduced ICU stays without increasing treatment costs, demonstrating the economic advantage of implementing CytoSorb therapy in intensive care units.

Conclusion

Dr. Chan concluded the report by emphasizing the importance of addressing current challenges while focusing on long-term growth strategies. With a robust pipeline for DrugSorb-ATR, they are poised to take advantage of substantial opportunities in the U.S. market. The company remains committed to operational excellence, regulatory compliance, and ultimately delivering value for stakeholders in healthcare.

Upcoming Investor Call

For those interested in detailed insights, CytoSorbents will host an earnings call on May 13, 2026, at 4:30 PM ET, which will be accessible live online from their investor relations webpage. Participants are encouraged to join early to engage fully in the question and answer segment.